COMPASS Pathways PLC Sponsored ADR $CMPS Stock Holdings Lifted by GMT Capital Corp

Key Points

• GMT Capital Corp increased its stake in COMPASS Pathways by 15.1% in Q1, now holding approximately 1.92% of the company valued at $5.1 million.
• COMPASS Pathways stock opened at $4.42 and has been trading between a 52-week low of $2.25 and a high of $8.08.
• Analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year, with ratings indicating a consensus "Moderate Buy" and a target price of $16.29.

GMT Capital Corp increased its position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 15.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,781,718 shares of the company's stock after purchasing an additional 233,918 shares during the period. GMT Capital Corp owned 1.92% of COMPASS Pathways worth $5,096,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of CMPS. Cerity Partners LLC acquired a new position in COMPASS Pathways in the first quarter worth about $29,000. GAMMA Investing LLC grew its stake in COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after purchasing an additional 5,003 shares in the last quarter. Ethos Financial Group LLC acquired a new position in COMPASS Pathways in the first quarter worth about $35,000. Flagship Harbor Advisors LLC grew its stake in COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after purchasing an additional 3,134 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in COMPASS Pathways in the first quarter worth about $41,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on CMPS shares. Canaccord Genuity Group restated a "buy" rating and issued a $15.00 target price on shares of COMPASS Pathways in a research note on Friday, August 1st. HC Wainwright decreased their target price on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, August 4th. Evercore ISI restated an "in-line" rating and issued a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a research note on Tuesday, May 27th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, COMPASS Pathways has a consensus rating of "Moderate Buy" and a consensus target price of $16.29.

COMPASS Pathways Price Performance

NASDAQ:CMPS traded up $0.19 during midday trading on Wednesday, hitting $4.71. 1,467,279 shares of the stock were exchanged, compared to its average volume of 1,808,158. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $7.53. The company has a market capitalization of $451.88 million, a price-to-earnings ratio of -2.56 and a beta of 2.17. The business has a 50-day moving average price of $4.03 and a two-hundred day moving average price of $3.85. The company has a current ratio of 8.82, a quick ratio of 8.82 and a debt-to-equity ratio of 0.16.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Sell-side analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.